Rituximab in refractory Vogt–Koyanagi–Harada disease

INTRODUCTION: Vogt–Koyanagi–Harada (VKH) prognosis depends on early recognition and treatment; chronic disease may be developed when either delayed or inadequate treatment is performed, whereas other cases despite correct treatment are refractory to different drugs and also become chronic. We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolz-Marco, Rosa, Gallego-Pinazo, Roberto, Díaz-Llopis, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223341/
https://www.ncbi.nlm.nih.gov/pubmed/21744181
http://dx.doi.org/10.1007/s12348-011-0027-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223341/
https://www.ncbi.nlm.nih.gov/pubmed/21744181
http://dx.doi.org/10.1007/s12348-011-0027-9

Ejemplares similares